Literature DB >> 2288878

A single Cys706 to Phe substitution in the retinoblastoma protein causes the loss of binding to SV40 T antigen.

Y J Bignon1, J Y Shew, D Rappolee, S L Naylor, E Y Lee, J Schnier, W H Lee.   

Abstract

Most naturally occurring mutants of the retinoblastoma (RB) protein contain large deletions or truncations. The small cell lung carcinoma cell line H209 contains a normal-sized but unphosphorylated RB protein (Hensel et al., Cancer Res., 50: 3067-3072, 1990), which fails to form a complex with SV40 T antigen, suggesting that the RB gene of H209 may contain a subtle mutation. To define this mutation, the RB complementary DNA and genomic DNA were sequenced, revealing a point mutation in exon 21 that changed a G to a T. This results in an amino acid substitution of a Phe for Cys706. The mutant RB complementary DNA was used as a template for in vitro transcription and translation to synthesize the mutated protein. The resulting protein failed to bind to SV40 T antigen, demonstrating that a single missense mutation of the RB gene led to the complete inactivation of the ability of the RB protein to bind T antigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2288878

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  10 in total

1.  RRB1 and RRB2 encode maize retinoblastoma-related proteins that interact with a plant D-type cyclin and geminivirus replication protein.

Authors:  R A Ach; T Durfee; A B Miller; P Taranto; L Hanley-Bowdoin; P C Zambryski; W Gruissem
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice.

Authors:  A Y Nikitin; M I Juárez-Pérez; S Li; L Huang; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Mutations of N-terminal regions render the retinoblastoma protein insufficient for functions in development and tumor suppression.

Authors:  D J Riley; C Y Liu; W H Lee
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

4.  Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.

Authors:  Satoko Iwahori; Angie C Umaña; Halena R VanDeusen; Robert F Kalejta
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

5.  c-Myc overexpression uncouples DNA replication from mitosis.

Authors:  Q Li; C V Dang
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

6.  A cancer derived mutation in the retinoblastoma gene with a distinct defect for LXCXE dependent interactions.

Authors:  Shauna A Henley; Sarah M Francis; Jordan Demone; Peter Ainsworth; Frederick A Dick
Journal:  Cancer Cell Int       Date:  2010-03-18       Impact factor: 5.722

7.  Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Authors:  Grant A Darnell; Toni M Antalis; Ricky W Johnstone; Brett W Stringer; Steven M Ogbourne; David Harrich; Andreas Suhrbier
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6.

Authors:  P L Chen; D J Riley; S Chen-Kiang; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression.

Authors:  A J Udvadia; D J Templeton; J M Horowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.

Authors:  S M Stirdivant; H E Huber; D R Patrick; D Defeo-Jones; E M McAvoy; V M Garsky; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.